Beijing Double-Crane Pharmaceutical Launches Generic Lipid-Regulating Drug
This article was originally published in PharmAsia News
Executive Summary
Beijing Double-Crane Pharmaceutical recently launched its latest generic drug pitavastatin calcium for lipid regulation. This represents a significant milestone as it shows a Chinese pharmaceutical company has achieved the capability of developing and producing global-standard drug. Patented pitavastatin calcium was initially launched in Japan in 2003. Beijing Double-Crane received approval from China's State FDA for the generic drug in 2008, and it into large-scale production. Currently, the company's annual output of over 50 million tablets can meet domestic demand. Aiming to become a branded generic drug maker with international competency, Double-Crane has raised its overall quality management level by applying for cGMP authentication. (Click here for more - Chinese language)